Jean Ching-Yi Tien
Overview
Explore the profile of Jean Ching-Yi Tien including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
448
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang J, Chang Y, Zhou K, Huang W, Tien J, Zhang P, et al.
J Med Chem
. 2025 Mar;
PMID: 40080446
Cyclin-dependent kinases 12 and 13 (CDK12/13) have emerged as promising therapeutic targets for castration-resistant prostate cancer (CRPC) and other human cancers. Despite the development of several CDK12/13 inhibitors, challenges remain...
2.
Tien J, Luo J, Chang Y, Zhang Y, Cheng Y, Wang X, et al.
Cell Rep Med
. 2024 Oct;
5(10):101758.
PMID: 39368479
Biallelic loss of cyclin-dependent kinase 12 (CDK12) defines a metastatic castration-resistant prostate cancer (mCRPC) subtype. It remains unclear, however, whether CDK12 loss drives prostate cancer (PCa) development or uncovers pharmacologic...
3.
Chang Y, Wang X, Yang J, Tien J, Mannan R, Cruz G, et al.
Cell Rep Med
. 2024 Oct;
5(10):101752.
PMID: 39353441
Cyclin-dependent kinases 12/13 play pivotal roles in orchestrating transcription elongation, DNA damage response, and maintenance of genomic stability. Biallelic CDK12 loss has been documented in various malignancies. Here, we develop...
4.
Parolia A, Eyunni S, Verma B, Young E, Liu Y, Liu L, et al.
Nat Genet
. 2024 Sep;
56(10):2132-2143.
PMID: 39251788
Androgen receptor (AR) is a ligand-responsive transcription factor that drives terminal differentiation of the prostatic luminal epithelia. By contrast, in tumors originating from these cells, AR chromatin occupancy is extensively...
5.
Wang X, Qiao Y, Asangani I, Ateeq B, Poliakov A, Cieslik M, et al.
Cancer Cell
. 2024 Aug;
42(8):1471.
PMID: 39137731
No abstract available.
6.
He T, Xiao L, Qiao Y, Klingbeil O, Young E, Wu X, et al.
Cancer Cell
. 2024 Jul;
42(8):1336-1351.e9.
PMID: 39029462
The POU2F3-POU2AF2/3 transcription factor complex is the master regulator of the tuft cell lineage and tuft cell-like small cell lung cancer (SCLC). Here, we identify a specific dependence of the...
7.
Choi J, Qiao Y, Kryczek I, Yu J, Gurkan J, Bao Y, et al.
Nat Commun
. 2024 Jun;
15(1):5487.
PMID: 38942798
Cancer treatment continues to shift from utilizing traditional therapies to targeted ones, such as protein kinase inhibitors and immunotherapy. Mobilizing dendritic cells (DC) and other myeloid cells with antigen presenting...
8.
Luo J, Chen Z, Qiao Y, Tien J, Young E, Mannan R, et al.
bioRxiv
. 2024 Apr;
PMID: 38586029
Prostate cancer is an exemplar of an enhancer-binding transcription factor-driven disease. The androgen receptor (AR) enhanceosome complex comprised of chromatin and epigenetic coregulators assembles at enhancer elements to drive disease...
9.
Tien J, Chang Y, Zhang Y, Chou J, Cheng Y, Wang X, et al.
bioRxiv
. 2024 Apr;
PMID: 38562774
Biallelic loss of cyclin-dependent kinase 12 () defines a unique molecular subtype of metastatic castration-resistant prostate cancer (mCRPC). It remains unclear, however, whether loss is sufficient to drive prostate cancer...
10.
Choi J, Qiao Y, Kryczek I, Yu J, Gurkan J, Bao Y, et al.
bioRxiv
. 2024 Mar;
PMID: 38464258
The modern armamentarium for cancer treatment includes immunotherapy and targeted therapy, such as protein kinase inhibitors. However, the mechanisms that allow cancer-targeting drugs to effectively mobilize dendritic cells (DCs) and...